Company intelligence / Profile preview

GrowthWorks

Vancouver, British Columbia, Canadagrowthworks.io ↗

Ownership: Private
Employees: ~2
Development stage: Phase 3

Overview

GrowthWorks Canadian Fund Ltd. has been in CCAA proceedings (Canadian equivalent of Chapter 11) and has been liquidating its portfolio investments. As of December 2022, it was seeking court approval to wind up the fund and make shareholder distributions within 24 months[9]. The fund is expected to cease its liquidation efforts and make a final cash distribution to shareholders by March 31, 2025[3].

Industry: Investors

Drug pipeline

3 assets

quizartinib

Phase 3

Indications: Acute myeloid leukemia

2 more assets in the full pipeline.

Request access →

Partnerships

Rosetta Capital

Beyond the preview

Go deeper on GrowthWorks.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GrowthWorks.

Explore the full profile